Switch to:
Also traded in: Canada, Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash to Debt No Debt
AEZS's Cash to Debt is ranked higher than
97% of the 940 Companies
in the Global Biotechnology industry.

( Industry Median: 101.30 vs. AEZS: No Debt )
Ranked among companies with meaningful Cash to Debt only.
AEZS' s Cash to Debt Range Over the Past 10 Years
Min: 0.44  Med: 79.49 Max: No Debt
Current: No Debt
Equity to Asset 0.37
AEZS's Equity to Asset is ranked lower than
80% of the 710 Companies
in the Global Biotechnology industry.

( Industry Median: 0.70 vs. AEZS: 0.37 )
Ranked among companies with meaningful Equity to Asset only.
AEZS' s Equity to Asset Range Over the Past 10 Years
Min: -0.34  Med: 0.37 Max: 0.98
Current: 0.37
-0.34
0.98
F-Score: 3
Z-Score: -9.97
M-Score: 3.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -4565.13
AEZS's Operating margin (%) is ranked lower than
88% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.21 vs. AEZS: -4565.13 )
Ranked among companies with meaningful Operating margin (%) only.
AEZS' s Operating margin (%) Range Over the Past 10 Years
Min: -339954.55  Med: -85.96 Max: 5.83
Current: -4565.13
-339954.55
5.83
Net-margin (%) -6168.47
AEZS's Net-margin (%) is ranked lower than
91% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -76.14 vs. AEZS: -6168.47 )
Ranked among companies with meaningful Net-margin (%) only.
AEZS' s Net-margin (%) Range Over the Past 10 Years
Min: -150581.82  Med: -67.86 Max: 110.36
Current: -6168.47
-150581.82
110.36
ROE (%) -272.62
AEZS's ROE (%) is ranked lower than
94% of the 855 Companies
in the Global Biotechnology industry.

( Industry Median: -31.69 vs. AEZS: -272.62 )
Ranked among companies with meaningful ROE (%) only.
AEZS' s ROE (%) Range Over the Past 10 Years
Min: -703.16  Med: -109.59 Max: 125.8
Current: -272.62
-703.16
125.8
ROA (%) -82.96
AEZS's ROA (%) is ranked lower than
84% of the 936 Companies
in the Global Biotechnology industry.

( Industry Median: -26.89 vs. AEZS: -82.96 )
Ranked among companies with meaningful ROA (%) only.
AEZS' s ROA (%) Range Over the Past 10 Years
Min: -57.37  Med: -25.52 Max: 11.16
Current: -82.96
-57.37
11.16
ROC (Joel Greenblatt) (%) -9747.54
AEZS's ROC (Joel Greenblatt) (%) is ranked lower than
87% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: -360.35 vs. AEZS: -9747.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
AEZS' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -1671.14  Med: -751.77 Max: 26.26
Current: -9747.54
-1671.14
26.26
Revenue Growth (3Y)(%) -95.50
AEZS's Revenue Growth (3Y)(%) is ranked lower than
93% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: 3.30 vs. AEZS: -95.50 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
AEZS' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -31.00 Max: 141
Current: -95.5
0
141
EBITDA Growth (3Y)(%) -40.40
AEZS's EBITDA Growth (3Y)(%) is ranked lower than
88% of the 489 Companies
in the Global Biotechnology industry.

( Industry Median: -1.10 vs. AEZS: -40.40 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
AEZS' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -19.10 Max: 33.5
Current: -40.4
0
33.5
EPS Growth (3Y)(%) -42.50
AEZS's EPS Growth (3Y)(%) is ranked lower than
87% of the 499 Companies
in the Global Biotechnology industry.

( Industry Median: -5.10 vs. AEZS: -42.50 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
AEZS' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -20.00 Max: 67.6
Current: -42.5
0
67.6
» AEZS's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-08-13)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q2 2015

AEZS Guru Trades in Q2 2015

Jim Simons 3,176,850 sh (+463.57%)
» More
Q3 2015

AEZS Guru Trades in Q3 2015

Jim Simons 11,284,993 sh (+255.23%)
» More
Q4 2015

AEZS Guru Trades in Q4 2015

Jim Simons 487,833 sh (-95.68%)
» More
Q1 2016

AEZS Guru Trades in Q1 2016

Jim Simons 516,833 sh (+5.94%)
» More
» Details

Insider Trades

Latest Guru Trades with AEZS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology
Compare:NAS:CNAT, ROCO:4169, XKRX:036480, XPAR:ALQGC, ASX:MDC, OTCPK:EMIS » details
Traded in other countries:AEZ.Canada, ET82.Germany,
AEterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing novel treatments in oncology, endocrinology and women's health.

AEterna Zentaris Inc is incorporated on September 12, 1990 under the Canada Business Corporations Act (the CBCA) and continues to be governed by the CBCA. The Company is an oncology and endocrinology drug development company investigating treatments for various unmet medical needs. Its pipeline encompasses compounds at all stages of development from drug discovery through to marketed products. Its oncology pipeline also encompasses other earlier-stage programs, including AEZS-112, an oral anticancer agent which involves three mechanisms of action such as tubulin, topoisomerase II and angiogenesis inhibition which has completed a Phase 1 trial in advanced solid tumors and lymphoma. Additionally, several novel targeted anticancer candidates such as AEZS-120, a live recombinant oral tumor vaccine candidate, as well as PI3K/Erk inhibitors, including AEZS-129, AEZS-134 and AEZS-136, are currently in preclinical development. In endocrinology, the Company is preparing the filing of an NDA in the U.S. for the registration of AEZS-130, an oral ghrelin agonist, as a diagnostic test for adult growth hormone deficiency (AGHD). A Phase 3 trial under a SPA with the FDA has been completed in this indication. Furthermore, AEZS-130 is in a Phase 2A trial for the treatment of cancer-induced cachexia.

Ratios

vs
industry
vs
history
P/B 2.11
AEZS's P/B is ranked higher than
70% of the 1025 Companies
in the Global Biotechnology industry.

( Industry Median: 3.36 vs. AEZS: 2.11 )
Ranked among companies with meaningful P/B only.
AEZS' s P/B Range Over the Past 10 Years
Min: 0.58  Med: 1.97 Max: 44.27
Current: 2.11
0.58
44.27
P/S 11.63
AEZS's P/S is ranked higher than
51% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: 12.41 vs. AEZS: 11.63 )
Ranked among companies with meaningful P/S only.
AEZS' s P/S Range Over the Past 10 Years
Min: 0.35  Med: 2.37 Max: 3761.9
Current: 11.63
0.35
3761.9
Current Ratio 6.46
AEZS's Current Ratio is ranked higher than
62% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.55 vs. AEZS: 6.46 )
Ranked among companies with meaningful Current Ratio only.
AEZS' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 3.33 Max: 50.67
Current: 6.46
0.92
50.67
Quick Ratio 6.46
AEZS's Quick Ratio is ranked higher than
63% of the 913 Companies
in the Global Biotechnology industry.

( Industry Median: 4.27 vs. AEZS: 6.46 )
Ranked among companies with meaningful Quick Ratio only.
AEZS' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 3.10 Max: 49
Current: 6.46
0.92
49
Days Sales Outstanding 240.06
AEZS's Days Sales Outstanding is ranked lower than
91% of the 606 Companies
in the Global Biotechnology industry.

( Industry Median: 63.27 vs. AEZS: 240.06 )
Ranked among companies with meaningful Days Sales Outstanding only.
AEZS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 14.15  Med: 61.03 Max: 19345
Current: 240.06
14.15
19345

Valuation & Return

vs
industry
vs
history
Price/Net Cash 6.53
AEZS's Price/Net Cash is ranked lower than
59% of the 670 Companies
in the Global Biotechnology industry.

( Industry Median: 5.01 vs. AEZS: 6.53 )
Ranked among companies with meaningful Price/Net Cash only.
AEZS' s Price/Net Cash Range Over the Past 10 Years
Min: 1.78  Med: 5.48 Max: 125.24
Current: 6.53
1.78
125.24
Price/Net Current Asset Value 5.20
AEZS's Price/Net Current Asset Value is ranked lower than
52% of the 783 Companies
in the Global Biotechnology industry.

( Industry Median: 4.96 vs. AEZS: 5.20 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
AEZS' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.32  Med: 3.87 Max: 21.22
Current: 5.2
1.32
21.22
Price/Tangible Book 4.34
AEZS's Price/Tangible Book is ranked lower than
55% of the 949 Companies
in the Global Biotechnology industry.

( Industry Median: 3.90 vs. AEZS: 4.34 )
Ranked among companies with meaningful Price/Tangible Book only.
AEZS' s Price/Tangible Book Range Over the Past 10 Years
Min: 1.01  Med: 2.77 Max: 84.69
Current: 4.34
1.01
84.69
Price/Median PS Value 4.91
AEZS's Price/Median PS Value is ranked lower than
92% of the 726 Companies
in the Global Biotechnology industry.

( Industry Median: 0.93 vs. AEZS: 4.91 )
Ranked among companies with meaningful Price/Median PS Value only.
AEZS' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.21  Med: 1.18 Max: 1380
Current: 4.91
0.21
1380
Earnings Yield (Greenblatt) (%) -2500.00
AEZS's Earnings Yield (Greenblatt) (%) is ranked lower than
100% of the 1090 Companies
in the Global Biotechnology industry.

( Industry Median: -9.50 vs. AEZS: -2500.00 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
AEZS' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 15.8  Med: 192.45 Max: 12762.4
Current: -2500
15.8
12762.4

More Statistics

Revenue (TTM) (Mil) $0.71
EPS (TTM) $ -22.82
Beta0.42
Short Percentage of Float9.89%
52-Week Range $2.60 - 31.38
Shares Outstanding (Mil)9.93

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2 18 18
EPS ($) -3.52 -1.42 -0.92
EPS without NRI ($) -3.52 -1.42 -0.92
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
» More Articles for NAS:AEZS

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
Can Keryx Succeed Without Partnership? Apr 24 2012 
Keryx Still Has High Potential from Zerenex Apr 12 2012 
Opportunistic Coat-tailing Jan 05 2010 

More From Other Websites
Aeterna Zentaris Elects Ms. Carolyn Egbert as Independent Chair of the Board May 23 2016
Aeterna Zentaris Announces Election of Directors at 2016 Shareholders' Meeting May 10 2016
Aeterna Zentaris reports 1Q loss May 09 2016
Aeterna Zentaris reports 1Q loss May 09 2016
Aeterna Zentaris Reports First Quarter 2016 Financial and Operating Results May 09 2016
Aeterna Zentaris Acquires Exclusive U.S. Promotional Rights for APIFINY® Prostate Cancer Blood Test Apr 27 2016
Aeterna Zentaris to Announce First Quarter 2016 Financial and Operating Results on May 9, 2016 Apr 26 2016
Aeterna Zentaris Mails Information Circular in Connection with Annual Meeting of Shareholders Apr 08 2016
AETERNA ZENTARIS INC. Financials Apr 02 2016
Aeterna Zentaris Announces At the Market Issuance Program Apr 01 2016
Æterna Zentaris, Inc. :AEZS-US: Earnings Analysis: Q4, 2015 By the Numbers Apr 01 2016
Aeterna Zentaris reports 4Q loss Mar 29 2016
Aeterna Zentaris reports 4Q loss Mar 29 2016
Aeterna Zentaris Reports Fourth Quarter and Full-Year 2015 Financial and Operating Results Mar 29 2016
Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2015 Financial and Operating Results on... Mar 15 2016
Aeterna Zentaris Reports on Zoptrex™ Development Progress in China Mar 01 2016
Company Profile for Aeterna Zentaris Inc. Feb 26 2016
Aeterna Zentaris Commences Promotional Activities for APIFINY® Prostate Cancer Blood Test Feb 23 2016
Aeterna Zentaris Appoints Geneviève Lemaire as Vice President, Finance and Chief Accounting Officer Feb 18 2016
Aeterna Zentaris to Participate in 18th Annual BIO CEO & Investor Conference Seeking Partnering... Feb 01 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)